BR112013012627A2 - proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição - Google Patents

proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição

Info

Publication number
BR112013012627A2
BR112013012627A2 BR112013012627A BR112013012627A BR112013012627A2 BR 112013012627 A2 BR112013012627 A2 BR 112013012627A2 BR 112013012627 A BR112013012627 A BR 112013012627A BR 112013012627 A BR112013012627 A BR 112013012627A BR 112013012627 A2 BR112013012627 A2 BR 112013012627A2
Authority
BR
Brazil
Prior art keywords
composition
polynucleotide
flow meter
fuel flow
antigen binding
Prior art date
Application number
BR112013012627A
Other languages
English (en)
Inventor
Chun-Wa Chung
Garcy Peter Bembridge
Ian Kirby
Maria Feeney
Ruth Mcadam
Susannah Karen Ford
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013012627(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112013012627A2 publication Critical patent/BR112013012627A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Volume Flow (AREA)

Abstract

proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, método de tratar um paciente humano afetado com um distúrbio ou doença imflamatória, e uso da composição. métodos e sistemas para detectar fraude causada por adulteração de um medidor de fluxo de combustível. em uma forma de realização, o método compreende prover um medidor de fluxo de combustível para medir o fluxo de combustível líquido. o medidor de fluxo tem pelo menos um eixo suportando um rotor. o método compreende adicionalmente prover o medidor de fluxo com um sensor de deslocamento rotativo. também, o método compreende medir uma primeira posição angular do eixo no término de uma primeira transação de abastecimento, e medir uma segunda posição angular do eixo no início de uma segunda transação de abastecimento. finalmente, o método compreende comparar dados indicativos das primeiras e segunda posições angulares do eixo para determinar se ocorreu fraude.
BR112013012627A 2010-11-23 2011-11-21 proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição BR112013012627A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41649510P 2010-11-23 2010-11-23
PCT/EP2011/070604 WO2012069433A2 (en) 2010-11-23 2011-11-21 Antigen binding proteins

Publications (1)

Publication Number Publication Date
BR112013012627A2 true BR112013012627A2 (pt) 2016-10-04

Family

ID=45001764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012627A BR112013012627A2 (pt) 2010-11-23 2011-11-21 proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição

Country Status (38)

Country Link
US (4) US8916695B2 (pt)
EP (3) EP3369744A1 (pt)
JP (2) JP6351973B2 (pt)
KR (2) KR20130119948A (pt)
CN (1) CN103328508B (pt)
AR (1) AR083937A1 (pt)
AU (1) AU2011333878B2 (pt)
BR (1) BR112013012627A2 (pt)
CA (1) CA2818534A1 (pt)
CL (1) CL2013001466A1 (pt)
CO (1) CO6801627A2 (pt)
CY (1) CY1120448T1 (pt)
DK (1) DK2643352T3 (pt)
DO (1) DOP2013000113A (pt)
EA (1) EA027256B1 (pt)
ES (1) ES2681949T3 (pt)
HR (1) HRP20181092T1 (pt)
HU (1) HUE039412T2 (pt)
IL (1) IL226157B (pt)
JO (1) JO3455B1 (pt)
LT (1) LT2643352T (pt)
MA (1) MA34742B1 (pt)
ME (1) ME03069B (pt)
MX (1) MX351887B (pt)
MY (1) MY170404A (pt)
NZ (1) NZ610464A (pt)
PE (1) PE20140519A1 (pt)
PL (1) PL2643352T3 (pt)
PT (1) PT2643352T (pt)
RS (1) RS57502B1 (pt)
SG (2) SG190232A1 (pt)
SI (1) SI2643352T1 (pt)
TR (1) TR201810773T4 (pt)
TW (1) TWI504609B (pt)
UA (1) UA111954C2 (pt)
UY (1) UY33743A (pt)
WO (1) WO2012069433A2 (pt)
ZA (1) ZA201303541B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011313847B2 (en) 2010-10-13 2016-07-07 Janssen Biotech, Inc. Human oncostatin M antibodies and methods of use
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
WO2016046738A1 (en) 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
US10822406B2 (en) 2015-01-29 2020-11-03 Oxford University Innovation Limited Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR)
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
FR3090637A1 (fr) * 2018-12-21 2020-06-26 Universite De Poitiers Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
ATE382636T1 (de) * 2000-04-21 2008-01-15 Conaris Res Inst Ag Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
PE20090046A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
PT1730191E (pt) * 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
GB0407197D0 (en) * 2004-03-30 2004-05-05 Glaxo Group Ltd Immunoglobulins
CA2573745A1 (en) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
TWI397536B (zh) 2005-07-22 2013-06-01 基因重組之抗體組成物
MY157173A (en) * 2006-05-25 2016-05-13 Glaxo Group Ltd Modified humanised anti-interleukin-18
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
AU2011313847B2 (en) * 2010-10-13 2016-07-07 Janssen Biotech, Inc. Human oncostatin M antibodies and methods of use
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)

Also Published As

Publication number Publication date
AU2011333878A1 (en) 2013-05-09
SI2643352T1 (sl) 2018-12-31
UA111954C2 (uk) 2016-07-11
AU2011333878B2 (en) 2016-01-14
JO3455B1 (ar) 2020-07-05
TR201810773T4 (tr) 2018-08-27
CN103328508A (zh) 2013-09-25
EA201390537A1 (ru) 2014-01-30
RS57502B1 (sr) 2018-10-31
ME03069B (me) 2019-01-20
US20130251724A1 (en) 2013-09-26
HUE039412T2 (hu) 2018-12-28
AR083937A1 (es) 2013-04-10
CO6801627A2 (es) 2013-11-29
LT2643352T (lt) 2018-08-10
EP2643352B1 (en) 2018-05-02
US20150064201A1 (en) 2015-03-05
SG190232A1 (en) 2013-06-28
TW201235358A (en) 2012-09-01
UY33743A (es) 2012-06-29
ES2681949T3 (es) 2018-09-17
KR20130119948A (ko) 2013-11-01
DK2643352T3 (en) 2018-07-30
EP3211009A1 (en) 2017-08-30
IL226157B (en) 2020-10-29
NZ610464A (en) 2015-02-27
DOP2013000113A (es) 2013-12-15
MA34742B1 (fr) 2013-12-03
MX2013005843A (es) 2013-07-05
JP2014507373A (ja) 2014-03-27
PE20140519A1 (es) 2014-04-30
US8916695B2 (en) 2014-12-23
US20210017270A1 (en) 2021-01-21
US20170152312A1 (en) 2017-06-01
IL226157A0 (en) 2013-06-27
TWI504609B (zh) 2015-10-21
WO2012069433A3 (en) 2012-08-09
CN103328508B (zh) 2015-12-16
ZA201303541B (en) 2014-11-26
CL2013001466A1 (es) 2014-06-27
MX351887B (es) 2017-11-01
PL2643352T3 (pl) 2018-10-31
KR20180110199A (ko) 2018-10-08
US10808029B2 (en) 2020-10-20
JP6351973B2 (ja) 2018-07-04
SG10201500388PA (en) 2015-03-30
EA027256B1 (ru) 2017-07-31
US9605063B2 (en) 2017-03-28
CY1120448T1 (el) 2019-07-10
HRP20181092T1 (hr) 2018-09-21
KR101947356B1 (ko) 2019-02-12
JP2017078072A (ja) 2017-04-27
PT2643352T (pt) 2018-08-01
WO2012069433A2 (en) 2012-05-31
CA2818534A1 (en) 2012-05-31
EP3369744A1 (en) 2018-09-05
EP2643352A2 (en) 2013-10-02
MY170404A (en) 2019-07-27

Similar Documents

Publication Publication Date Title
BR112013012627A2 (pt) proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
WO2012076666A3 (en) Fuel dispenser flow meter sensor fraud prevention
BR112013026975A2 (pt) unidade de medidor de fluxo de combustível
BR112016009276A8 (pt) método e sistema para monitorar o fluxo de fluido em um conduto
Breyer et al. Better nephrology for mice—and man
BR112015022553A2 (pt) fluxímetro de fluido
EP2549237A3 (en) High-resolution non-contacting multi-turn sensing systems and methods
BR112012007951A2 (pt) administracao de teste de fluxo e os resultados do mesmo para poços de hidrocarboneto
WO2010092544A3 (en) Flow meter
BR112014006855B8 (pt) Sistema de medição de fluxo ultrassônico, método para medir fluxo de fluido, e, mídia legível por computador
NZ606495A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
BRPI0822593A2 (pt) Método para detectar, de modo audível, uma mudança de estado de fluxo de fluido em uma tubulação de medidor de fluxo, e, sistema para melhorar a precisão de um medidor de fluxo.
BR112014019564A8 (pt) Método para determinar a permeabilidade ou uma propriedade indicativa da permeabilidade de um reservatório
GB201302242D0 (en) Apparatus adapted to provide an indication of an angular position of an input member over multiple turns
BR112015029794A2 (pt) disposição para a detecção de um volume de distribuição, dispositivo, sistema de extração, métodos para a detecção de um volume de distribuição e para a medição de uma usina de proteção
BR112014008952A2 (pt) sensor para gás solúvel em fluido
BR112016001947A2 (pt) métodos e sistemas de calibração de modelo de terra estático usando testes de permeabilidade
EP3144670A3 (en) Anticancer agent sensitivity-determining marker
BR112012024619A2 (pt) sistema e método para avaliação de candidato a medicamento anticancer
WO2010080341A3 (en) A method for field-measuring fluid flow meters
FR2975483B1 (fr) Systeme et turbine comprenant un indicateur de fluage
BR112017027601A2 (pt) método de tomografia de poço cruzado, sistema para imagear uma formação de subsuperfície e método para obter informações sobre uma formação de subsuperfície
WO2011027332A3 (en) Microrna expression signature in peripheral blood of patients affected by hepatocarcinoma or hepatic cirrhosis and uses thereof
UA38918U (ru) Топливная система двигателя с участком для измерения расхода топлива
Han The human capital loss of air pollution in cities, China

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]